Full-Time
Confirmed live in the last 24 hours
Next-generation sequencing technology provider
$90k - $110kAnnually
Mid, Senior
Remote in USA
Remote role based in the Southeast.
You match the following Element Biosciences's candidate preferences
Employers are more likely to interview you if you match these preferences:
Element Biosciences specializes in next-generation sequencing (NGS) technology, primarily through its product, the AVITI System. This compact benchtop system provides high-quality DNA sequencing at a low cost, charging only $1 per million reads, which is significantly less than the industry average. The AVITI System is designed to deliver industry-leading accuracy, allowing users, including academic researchers and pharmaceutical companies, to maximize their resources. Element Biosciences differentiates itself from competitors by forming partnerships with other biotech firms, such as QIAGEN, to offer complete NGS workflows, enhancing the value of their product. Additionally, the company runs the 2023 AVITI for All Grant program, which provides free sequencing services to support research across various fields. The goal of Element Biosciences is to make high-quality sequencing accessible and affordable, thereby accelerating research and development in the biotechnology sector.
Company Size
201-500
Company Stage
Series D
Total Funding
$659.5M
Headquarters
San Diego, California
Founded
2017
Help us improve and share your feedback! Did you find this helpful?
100% company-paid medical, dental, & vision coverage
Flexible spending & health savings accounts
Premier mental health care
401(k) with immediately vested 4% company match
Company-paid Life and AD&D insurance
Stock option grants
Flexible time off
10 paid annual holidays
8-weeks paid parental leave
Newsletter Signup - Under Article / In Page"*" indicates required fields Precision medicine is a kind of treatment strategy that is tailored to individual patients, most of which is dependent on their genetic makeup. Genomics, which deals with the mapping of genomes, is a booming industry that aims to advance precision medicine to address a host of diseases. You may have heard of the big names in the business, like Illumina, Oxford Nanopore Technology, and Thermo Fisher Scientific. But there are a number of genomics startups that have sprouted up in the past decade or so to strengthen their sequencing technologies to aid in disease prevention and treatment. Here are seven genome sequencing startups that are making their mark in the industry.Element BiosciencesFounded in 2017, Element Biosciences shot to fame fairly quickly after the launch of its lab services. Its benchtop sequencing instrument AVITI has a dual flow cell layout and individually addressable lanes and you can perform two parallel runs and operate each side independently. Its alternative model, AVITI LT, is a lower-cost, lower-throughput solution that brings next-generation sequencing (NGS) to more labs.The core components of Element’s sequencing tool include an Avidite base chemistry, which circularizes, copies, and rolls each strand into tightly bound polonies – tiny clusters of identical DNA molecules – without the use of PCR and fluorescent avidites that bind to each polony creating ultrastable complexes. It also employs rolling circle amplification, which is a process that uses a circular DNA template to create long single-stranded DNA molecules to avoid errors such as index hopping – when sequencing reads are incorrectly assigned to the wrong sample in a pool. Its sought-after technology is called LoopSeq, which prepares libraries for long-read sequencing on the short-read Element AVITI System
The collaboration combines Revvity's expertise in newborn screening and rare disease detection with Element's AVITI(TM) sequencing system technology.
Element Biosciences, a U.S. biotech startup, has achieved unicorn status with a valuation over $1 billion and has raised over $680 million. CEO Molly He discussed the company's journey at the Web Summit in Lisbon, highlighting their DNA sequencing device, Aviti, which is used in numerous labs and hospitals. Initial funding included $5 million from Venrock, with subsequent rounds raising $15 million in Series A, $110 million in Series B, and contributions from major investors like Fidelity and RA Capital.
Element Biosciences has partnered with Integrated DNA Technologies (IDT) and Twist Bioscience to provide the necessary exome-targeting tools for the Trinity workflow
In July 2021, Qiagen partnered with Sysmex for the development and marketing of cancer companion diagnostic (CDx) solutions, leveraging Sysmex's Plasma-Safe-SeqS technology for NGS